Point72 Asset Management, L.P. 13D and 13G filings for Aeglea BioTherapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2022-02-14 4:25 pm Sale |
2021-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
Point72 Asset Management, L.P. | 2,244 0.100% |
-114,948 (-98.09%) |
Filing |
| 2021-02-16 3:14 pm Purchase |
2020-12-31 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
Point72 Asset Management, L.P. | 117,191 6.100% |
1,672 (+1.45%) |
Filing |
| 2020-10-26 4:36 pm Purchase |
2020-10-23 | 13G | Aeglea BioTherapeutics, Inc. AGLE |
Point72 Asset Management, L.P. | 115,519 6.200% |
115,519 (New Position) |
Filing |